ArticleEuropean journal of pediatrics2018
Health status of Polish children and adolescents after cancer treatment.
Article in European journal of pediatrics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 33 citations in OpenAlex.
- Incidence of and risk factors for chronic kidney disease in childhood cancer survivors.Pediatric nephrology (Berlin, Germany) · 2026Article
- Late pulmonary adverse effects in childhood and adolescent acute lymphoblastic leukaemia survivors: a cross-sectional ALL-STAR Lungs study.ERJ open research · 2025Article
- Adolescent Survivors of Childhood Cancer: Biopsychosocial Challenges and the Transition from Survival to Quality of Life.Children (Basel, Switzerland) · 2025Review
- Childhood cancer survivors: improving our practice today to reduce late, major surgical interventions tomorrow.Translational pediatrics · 2024Article
- Assessment of Metabolic Syndrome and Kidney and Heart Function in Childhood Cancer Survivors.Children (Basel, Switzerland) · 2023Article
- Apolipoproteins-New Biomarkers of Overweight and Obesity among Childhood Acute Lymphoblastic Leukemia Survivors?International journal of molecular sciences · 2022Article
- Article
- Biomarkers of Glucose Metabolism Alterations and the Onset of Metabolic Syndrome in Survivors of Childhood Acute Lymphoblastic Leukemia.International journal of molecular sciences · 2022Article
- Growth hormone therapy in short-stature patients with kyphoscoliosis: a literature review.EFORT open reviews · 2022Review
- Dimethylarginines in Children after Anti-Neoplastic Treatment.Medicina (Kaunas, Lithuania) · 2022Article
- Urinary Beta-2-Microglobulin and Late Nephrotoxicity in Childhood Cancer Survivors.Journal of clinical medicine · 2021Article
- The Burden of Late Effects and Related Risk Factors in Adolescent and Young Adult Cancer Survivors: A Scoping Review.Cancers · 2021Article
- Increased Levels of Adipocyte and Epidermal Fatty Acid-Binding Proteins in Acute Lymphoblastic Leukemia Survivors.Journal of clinical medicine · 2021Article
- Urine NGAL and KIM-1-Tubular Injury Biomarkers in Long-Term Survivors of Childhood Solid Tumors: A Cross-Sectional Study.Journal of clinical medicine · 2021Article
- Urine NGAL and KIM-1: tubular injury markers in acute lymphoblastic leukemia survivors.Cancer chemotherapy and pharmacology · 2020Observational
- Impairment of lung diffusion capacity-a new consequence in the long-term childhood leukaemia survivors.Annals of hematology · 2019Observational
- Risk factors for premature aging in childhood cancer survivors.Developmental period medicine · 2019Review
Corrections and comments
- Erratum issued
Authors and funding
12 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the last 40 years, considerable progress was made in the treatment of childhood cancer. Nearly 80% of children achieve long-term clinical remission or are permanently cured. This improvement is however not without sacrifice. This is the first Polish study analyzing the general health status and epidemiology of organ late effects in the cohort of Polish childhood and adolescent cancer survivors monitored by doctors and registered in the on-line national database for late effects (N = 1761). This tool collects information on previous therapy and current health status (medical history, physical examination, laboratory tests) of cancer survivors. The survivors are invited to take part in the follow-up examination 5 years after the end of treatment. In the study group, 207 survivors (11.75%) had no complaints; whereas in 1554 cases (88.25%), one or more symptoms/complaints suggesting organ dysfunction were reported. In the whole group, the circulatory problems were most common (31.7%); more than 20% of survivors presented complaints or abnormal function of the urinary tract and had skin, dental, skeletal/muscular problems, or difficulty with chewing. Obesity or short stature alone (21.4%) and a variety of endocrine problems (short stature, obesity, thyroid dysfunction, and gonads toxicity) were present in 323 patients (118 females 15.0% and 205 males 21.0%). Gonadal dysfunction, as the only problem, occurred in 75 girls (9.6%) and 131 boys (13.4%). In our cohort, severe or life-threatening health conditions (3 and 4 grade according to toxicity criteria) were present in low percentage, i.e., 0.2% in the circulatory system, 0.3% in the respiratory tract and, 0.7% in kidney insufficiency.
conclusionOur findings indicate that many childhood cancer survivors demonstrate numerous complaints, even a short time after treatment, suggesting the importance of regular follow-up examinations in subsequent years. What is Known: • Contemporary studies indicate that a significant number of childhood cancer survivors present different long-term side effects which influence their quality of life. What is New: • This is the first nationwide study performed in the largest cohort of Polish childhood cancer survivors concerning general health status and frequency of organ dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.